Concepedia

Mingzhu Zhu

MZ

Statistics

Publications

44

Citations

4.1K

H-Index

27

Active since

1997

Affiliations

Novavax (United States)(Current)

Peking University

Ministry of Education of the People's Republic of China

Peking University First Hospital

University of Maryland, Baltimore

Mingzhu Zhu is an author at Novavax (United States) specializing in immunology, life sciences, and vaccination.

ORCID

Publications per year

1997–2024

44

Publications

44

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

, , +17

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · New England Journal of Medicine · 2021 · 662 citations · Full text

, , +17

CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer

Nagarajan Ramesh, Ying Ge, David L. Ennist et al. · Clinical Cancer Research · 2006 · 243 citations

, , +12

Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.

S Zaremba, E Barzaga, Mingzhu Zhu et al. · PubMed · 1997 · 203 citations

, , +17

The tumor suppressor PTEN has a critical role in antiviral innate immunity

Shun Li, Mingzhu Zhu, Ruangang Pan et al. · Nature Immunology · 2015 · 190 citations

, , +16

1–5 of 44